Marked enhancement in vivo of paclitaxel's (taxol's) tumor-regressing activity by ATP-depleting modulation

Anti-Cancer Drugs

Volumn 7, Issue 6, 1996, Pages 655-659

  Martin, Daniel S ^a,b   Stolfi, Robert L ^a   Colofiore, Joseph R ^a   Dee Nord, L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Cathol Med Ctr Brooklyn Q   (United States)

Author keywords

ATP depletion; Biochemical modulation; Murine mammary tumors; Paclitaxel; Tumor regression

Indexed keywords

6 AMINONICOTINAMIDE; 6 METHYLTHIOINOSINE; ADENOSINE TRIPHOSPHATE; PACLITAXEL; SPARFOSIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MICROTUBULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION;

6-AMINONICOTINAMIDE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTIC ACID; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLTHIOINOSINE; MICE; PACLITAXEL; PHOSPHONOACETIC ACID; REMISSION INDUCTION;

EID: 0029861346     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199608000-00006     Document Type: Article

References (32)

1. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995; 332: 1004-14.
2. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979; 22: 665-7.
3. Schiff PB, Horwitz SB. Taxol stabilzes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980; 77: 1561-5.
4. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981; 91: 479-87.
5. Manfredi JJ, Horwitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 1984; 25: 83-125.
6. Martin SJ, Cotter TG. Disruption of microtubules induces an endogenous suicide pathway in human leukemia HL-60 cells. Cell Tissue Kinet 1991; 23: 545-59.
7. Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumor cell lines by widely diverging stimuli. Cell Prolif 1991; 24: 203-14.
8. Gelfand VI, Bershadsky AD. Microtubule dynamics: mechanisms, regulation, and function. Annu Rev Cell Biol 1991; 7: 93-116.
9. Bershadsky AD, Gelfand VI. ATP-dependent regulation of cytoplasmic microtubule disassembly. Proc Natl Acad Sci USA 1981; 78: 3610-3.
10. DeBrabander M, Geuens G, Nuydens R, Willebrords R, De Mey J. Microtubule assembly in living cells after release from nocodazole block: the effects of metabolic inhibitors, taxol and pH. Cell Biol Int Rep 1981; 5: 913-20.
11. Martin KJ, Vassallo CD, Teicher BA, Kaddurah-Dasuk R. Microtubule stabilization and potentiation of Taxol activity by the creatine analog cyclocreatine. Anti-Cancer Drugs 1995; 6: 419-26.
12. Stolfi RL, Colofiore JR, Nord LD, Koutcher JA, Martin DS. Biochemical modulation of tumor cell energy: regression of advanced, spontaneous murine breast tumors with a 5-fluorouracil-containing drug combination. Cancer Res 1992; 52: 4074-81.
13. Martin DS, Stolfi RL, Colofiore JR, et al. Apoptosis resulting from anti-cancer agent activity in vivo is enhanced by biochemical modulation of tumor cell energy. In: Lavin M, Watters D, eds. Programmed cell death. The cellular and molecular biology of apoptosis. Basel: Harwood Academic 1993: 279-96.
14. Martin DS, Stolfi RL, Colofiore JR, Nord LD. Biochemical modulation of tumor cell energy in vivo: II. A lower dose of Adriamycin is required and greater antitumor activity is induced when cellular energy is depressed. Cancer Invest 1994; 12: 296-307.
15. Koutcher JA, Alfieri A, Stolfi RL, et al. Potentiation of a three drug chemotherapy regimen by radiation. Cancer Res 1993; 53: 3518-23.
16. Colofiore JR, Stolfi RL, Nord LD, Martin DS. Biochemical modulation of tumor cell energy IV Evidence for the contribution of adenosine triphosphate (ATP) depletion to chemotherapeutically-induced tumor regression. Biochem Pharmacol 1995; 50: 1943-48.
17. Stolfi RL, Martin DS, Fugmann RA. Spontaneous murine mammary adenocarcinoma: model system for evaluation of combined methods of therapy. Cancer Chemother Rep 1971; 55: 239-51.
18. Martin DS, Fugmann RA, Stolfi RL, Hayworth PE. Solid tumor animal model therapeutically predictive for human breast cancer. Cancer Chemother Rep 1975; 5: 89-109.
19. Goldin A, Venditti JM, MacDonald JS, et al. Current results of the screening program at the Division of Cancer Treatment. National Cancer Institute. Eur J Cancer 1981; 17: 129-42.
20. Stolfi RL, Stolfi LM, Sawyer RC, Martin DS. Chemotherapeutic evaluation using clinical criteria in spontaneous, autochthonous murine breast tumors. J Natl Cancer Inst 1988; 80: 52-5.
21. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90: 9552-6.
22. 1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res 1994; 54: 4353-61.
23. Garcia P, Braguer D, Carles G, Briand D. Simultaneous combination of microtubule depolymerizing and stabilizing agents acts at low doses. Anti-Cancer Drugs 1995; 6: 533-44.
24. Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME, Huang Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 1993; 7: 563-8.
25. Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1995; 1: 506-26.
26. Berger NA. Poly(ADP-ribose) in the cellular response to DNA damage. Radiat Res 1985; 101: 4-15.
27. Berger NA, Berger SJ, Sudar DC, Distelhorst CW. Role of nicotinamide adenine dinucleotide and adenosine triphosphate in glucocorticoid-induced cytotoxicity in susceptible lymphoid cells. J Clin Invest 1987; 79: 1558-63.
28. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6308-11.
29. Nelson WG, Kastan MB. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA response pathways. Mol Cell Biol 1994; 14: 1815-23.
30. Tishler RB, Lamppu DM, Park S, Price B. Microtubuleact drugs Taxol, Vinblastine, and Nocodazole increase the levels of transcriptionally active p53. Cancer Res 1995; 55: 6021-5.
31. Pittman S, Geyp M, Tynan SJ, Gramacho CM, Stickland DH, Fraser MJ, Ireland CM. Tubulin in apoptotic cells. In: Lavin M, Watters D, eds. Programmed cell death. The cellular and molecular biology of apoptosis. Basel: Harwood Academic 1993: 315-23.
32. O'Dwyer PJ, Hudes GR, Colofiore J, et al. Phase I trial of Fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens. J Natl Cancer Inst 1991; 83: 1235-40.